ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1939

Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trail

Jia Wang1, Sheng-Xiao Zhang2, Fang-Yuan Hu3, Xiao-Juan Zheng1, Ting Cheng1, Na-Na Yu2, Wen-Xian Yang1, Chong Gao4, Hong-Yan Wen2 and Xiao-Feng Li5, 1Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, 2The Second Hospital of Shanxi Medical University, Taiyuan, China, 3Rheumatology, The Second Hospital of Shanxi Medical Univerity, Taiyuan City, China, 4Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, 5The Second Hospital of Shanxi Medical Univerity, Taiyuan, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: mTor, Regulatory cells, rheumatoid arthritis (RA) and treatment

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, October 22, 2018

Session Title: 4M106 ACR Abstract: RA–Treatments III: New Compounds & Biosimilars (1935–1940)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:  Patients with refractory rheumatoid arthritis (RA) have T-cell dysfunction that associates the activation of mTOR that is inhibited by rapamycin, which has been developed as a medication under the generic designation of sirolimus. Recently, we have reported that absolute number of peripheral regulatory T (Treg) cells reduced in RA patients. Since rapamycin has been reported to expand Tregs, in this study, we assessed safety, tolerance, and efficacy of sirolimus for RA treatment.

Methods:  We did a double-arm, open-label, and phase 1/2 trial of sirolimus in patients with RA at the Second Hospital of Shanxi Medical University (Taiyuan, Shanxi, China). Eligible participants (aged 18 to 65 years) fulfill the revised the 1987 ACR/EULAR criteria for the classification of RA and did not achieve remission with the conventional treatment over at least 2 years. We excluded patients with allergy or intolerance to sirolimus, with malignant disease or a history of malignancy, or with chronic or severe infection. Patients in control group (n=19) were given conventional glucocorticoids and DMARDs treatment. Patients in sirolimus group (n=38) were given not only conventional treatment, but also oral sirolimus at a starting dose of 0.5 mg on alternate days for 24 weeks. The demographic features, clinical manifestations and laboratory indicators were compared before and after the treatment. This trial is registered at Chinese Clinical Trial Registry, number ChiCTR-IPR-17010307.

Results:  There was no difference between sirolimus and control group in gender and age (P > 0.05). After 24 weeks of the sirolimus treatment, except C-reaction protein, there was a significant decrease in disease activity measures including DAS28, ESR, the number of tender joints and swollen joints (P < 0.001). Patients with sirolimus treatment had a significant increase in the number of Tregs and a lower DMARDs usage rate (P < 0.05). There was no difference in blood routine, liver and renal functions both before and after the treatment between two groups (P > 0.05).

Conclusion:  Sirolimus treatment selectively up-regulated Tregs and partly decreased the usage of DMARDs without over-treatment and evaluated side effect. The further study is required to increase the RA patients in sirolimus and conventional treatment groups.


Disclosure: J. Wang, None; S. X. Zhang, None; F. Y. Hu, None; X. J. Zheng, None; T. Cheng, None; N. N. Yu, None; W. X. Yang, None; C. Gao, None; H. Y. Wen, None; X. F. Li, None.

To cite this abstract in AMA style:

Wang J, Zhang SX, Hu FY, Zheng XJ, Cheng T, Yu NN, Yang WX, Gao C, Wen HY, Li XF. Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trail [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/sirolimus-treatment-in-patients-with-refractory-rheumatoid-arthritis-a-double-arm-open-label-phase1-2-trail/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sirolimus-treatment-in-patients-with-refractory-rheumatoid-arthritis-a-double-arm-open-label-phase1-2-trail/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.